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Abstract-The inhibition of renal ornithine decarboxylase (ODC) by aminoglycoside antibiotics was 
characterized in the postmitochondrial fraction of a kidney homogenate from adult pigmented guinea 
pigs. Enzymatic activity was defined as the rate of decarboxylation of [‘“C] ornithine sensitive to a specific 
ODC inhibitor, ~-difluoromethylornithine (DFMO). The Km for ornithine was 61 t 32 FM. There were 
two forms of the enzyme with respect to their affinity for pyridoxal phosphate (PLP): (I) K,,, = 
2.1 t 1.8 PM; (II) K,,, = 36.2 t 12.7 PM. Putrescine, a known ODC inhibitor, acted competitively on the 
renal enzyme with Ki = 1.7 + 1.4 mM. Aminoglycoside antibiotics inhibited ODC by an uncompetitive 
mechanism with inhibitor constants of comparable magnitude: neomycin, K, = 1.3 +- 0.1 mM; genta- 
micin, Ki = 1.6 + 0.1 mM; kanamycin, Ki = 1.9 + 0.2 mM; and netihnicin, Ki = 1.7 2 0.2 mM. Neo- 
mycin inhibited both forms of the enzyme (low and high aftinity for PLP) uncompetitively with similar 
inhibitor constants (1.5 + 0.3 and 1.8 2 0.4 mM respectively), suggesting a single mechanism of action. 
Inhibition of ODC suggests that aminoglycoside-polyamine interactions may be an important component 
of the sequence of biochemical events associated with aminoglycoside toxicity. 
Aminoglycoside antibiotics such as neomycin and 
gentamicin and the polyamines putrescine, sper- 
midine and spermine not only share chemical fea- 
tures as polycations but also a number of 
pharmacological actions. Discrete interactions 
between aminoglycosides and polyamines which may 
relate to the mechanism of aminoglycoside toxicity 
have been described in bacteria as well as mamm~i~ 
tissues. For example, spermidine and the amino- 
glycosides competitively inhibit binding of dihydro- 
streptomycin (DHS) to cell wall teichoic acids 
isolated from various gram-positive eubacteria [ 11. 
Spermine and spermidine share renal binding sites 
with aminoglycosides [2], and the aminoglycosides 
compete for active polyamine transport in both the 
kidney [3] and the inner ear [4]. 
Bioche~cal studies to elucidate nephrotoxic and 
ototoxic actions of aminoglycosides have provided 
evidence for a multi-step model of toxicity which 
proposes an initial interaction between the drugs 
and the plasma membrane, followed by an energy- 
dependent uptake process competitive with poly- 
amines, and finally intracellular binding [4-6]. To 
characterize further the potential role of amino- 
glycoside interactions with polyamines in this injury 
cascade, we studied the effects of aminoglycosides 
on the activity of renal ornithine decarboxylase. 
Ornithine decarboxylase (ODC) is a key enzyme 
in the polyamine biosynthetic pathway and subject 
to feedback-inhibition by its reaction product 
putrescine, as well as by the other polyamines sper- 
midine and spermine [7]. In view of the known 
interactions between the polyamines and amino- 
glycosides, it is plausible that the aminoglycosides 
may affect this enzyme and, thus, cellular mech- 
anisms regulated by polyamines. 
* To whom correspondence should be addressed. 
METHODS 
Kidneys from pigmented guinea pigs (2W250 g, 
Murphy Breeding Laboratories, Plainsfield, IN) 
were homogenized in 50mM sodium N-Zhydroxy- 
ethyl-1-piperazine-N’-2-ethane sulfonic acid 
(HEPES), 2 mM dithioerythritol (DTE) and 50 PM 
pyridoxal phosphate (PLP), pH 7.2, using a Polytron 
(Brinkmann, Switzerland) for 10sec. No PLP was 
added to the homogenization in experiments where 
the final PLP concentrations were varied. The homo- 
genate (20%, w/v) was centrifuged at 13,OOOg for 
20 min at 4”, and the supematant fraction was frozen 
until assayed for ODC activity by a modification of 
the method of Russell and Snyder [8]. Aliquots of 
the supernatant fraction were incubated in test tubes 
with separate reservoirs for the incubation medium 
and H2S04 and fitted with stoppers holding filter 
paper disks saturated with 15 ~1 of 40% KOH. Incu- 
bation was for 60 min at 37” in a total reaction volume 
of 100 ~1 containing 50 mM HEPES, 2 mM DTE, 
0.1 mM EDTA, and 20 pg bovine serum albumin 
(BSA), pH 7.2. Ornithine concentration was 100 PM 
(L-[l-14C]ornithine, 52.4 mCi/mmol; New England 
Nuclear, Boston, MA) and PLP, 50 PM, except when 
the K,,, for these substances or the Ki values for the 
aminoglycosides were determined. In those experi- 
ments, ornithine was varied from 25 to 100 MM, and 
PLP from 0.5 to 100 PM. Reactions were terminated 
by combining 2004 of 4 N HrS04 with the incu- 
bation medium and post-incubating for 30min to 
allow for complete liberation of “C02 and absorp- 
tion onto the KOH-saturated filter. Radioactivity on 
the filter disks was quantitated by liquid scintillation 
counting. Control incubations to account for non- 
specific or nonenzymatic decarboxylation were per- 
formed in each set of experiments by adding 500 PM 
c+difluoromethylornithine (DFMO), a specific, irre- 
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Fig. 1. (A) Effects of protein concentration on the rate of CO, formation. Experiments were carried 
out as described in Methods, and the protein concentration in the assay was varied as indicated. 
Individual points represent means * SD of three incubations each. (B) CO2 formation as a function of 
the time of incubation. Experiments were carried out as described in Methods with incubation times 
varied as indicated. Points represent averages of two incubations each. Open circles denote experiments 
in the presence of DFMO (500 PM). 
versible inhibitor of ODC, or by substituting BSA 
(2Opg) for the enzyme fraction. Protein was deter- 
mined with the Bio-Rad assay (Bio-Rad Labora- 
tories, Richmond, CA) using BSA as a standard. 
The inhibition by neomycin (Fig. 2, insert) and all 
other compounds was examined by linear regression 
analysis of Lineweaver-Burk plots using the Enzpack 
analytical software (Elsevier Biosoft, Amsterdam). 
Inhibitor constants were calculated according to 
Bergmeyer [9] from assays with various inhibitor 
concentrations. 
22.8 * 7.8 (I) and 109.7 + 38.1 pmol COz.hr-‘. 
mg-’ (II). In contrast, a single K,,, of 61 + 32pM 
was evident for ornithine. For the standard assay 
conditions, V,,,,, ranged from 110 to 142 pmol 
COZ. hr-’ . (mg protein)-’ for different preparations 
of the 13,OOOg supernatant fraction. 
DFMO was a gift from the Merrell Dow Research 
Institute (Cincinnati, OH). All other chemicals were 
purchased from the Sigma Chemical Co. (St. Louis, 
MO). 
The addition of neomycin to the assay induced a 
dose-dependent decrease of ODC activity with a 
half-maximal inhibition in the millimolar range (Fig. 
2). Neomycin had no effect on the blank values, i.e. 
the decarboxylation in the presence of DFMO or 
with BSA only. The aminoglycoside antibiotics neo- 
mycin, kanamycin, gentamicin, and netilmicin all 
inhibited ODC in an uncompetitive manner (Fig. 
RESULTS Table 1. Inhibition of ornithine decarboxylase 
Initial experiments demonstrated that the for- 
mation of CO2 from [14C]ornithine by the renal 
postmitochondrial fraction was essentially linear with 
protein concentrations up to 200 pg in the assay (Fig. 
1A) and incubation times up to 2 hr, the longest time 
tested (Fig. 1B). Enzymatic activity was abolished 
when lo&500 PM DFMO was added. An incubation 
time of 60min and protein concentrations below 
200 pg were selected for all subsequent studies. 
Agent K, (mM) (N) Type of inhibition 
Neomycin 1.3 rt 0.1 (4) Uncompetitive 
Gentamicin 1.6 2 0.1 (3) Uncompetitive 
Netilmicin 1.7 * 0.2 (5) Uncompetitive 
Kanamycin 1.92 0.2 (4) Uncompetitive 
Putrescine 1.7 2 1.4 (3) Competitive 
Values represent means 2 SD of (N) independent 
Since previously reported data on renal ODC 
come from studies on the rat, mouse or hamster, 
kinetic parameters were determined for the enzyme 
preparation from the guinea pig. The analysis of the 
PLP dependence of the reaction indicated two K,,, 
values for PLP: (I) 2.1 2 1.8pM and (II) 
36.2 * 12.7 ,uM with corresponding V,,,,, values of 
experiments. In each experiment, duplicate or triplicate 
incubations were carried out at each of four different 
ornithine concentrations (25-100 PM). Intercepts were 
determined by linear regression analysis of Lineweaver- 
Burk plots. Correlation coefficients for the individual 
analyses were: ornithine in the absence of inhibitors, 
~0.99; putrescine and gentamicin, BO.94; neomycin, 0.85 
to 0.93; kanamycin, 0.81 to 0.98; and netilmicin, 0.78 to 
0.99. 
Aminogly~side inhibition of renal ornithine decarboxylase 
Fig. 2. Inhibition of omithine decarboxylase activity by neomycin. Experiments were carried out as 
described in Methods with neomycin added as indicated. Values are expressed as percent of control 
ODC activity (in the absence of drug) and represent means f SD of four to six incubations each. Control 
ODC values were 61.8 rt 14.6 pmol CO*. hr-’ . (mg protein)-‘, N = 21. Inhibition by 0.5 mM neomycin 
and above was significant (P < 0.01, Student’s unpaired t-test). Insert: Lineweaver-l3urk analysis of 
ODC inhibition by neomycin. mriments were conducted as described in Methods with various 
concentrations of ornithine (25-100 m) in the absence (W) and presence (0) of 1 mM neomycin. V = 
pmol COz*hr-‘.(mg protein)-‘; S = [ornithine, mM]. 
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2, insert; Table 1) with similar inhibitor constants 
ranging from Ki = 1.3 2 0.1 mM (neomycin) to Ki = 
1.9 2 0.2 mM (kanamycin). The two forms of the 
enzyme with respect to their apparent K, for PLP 
were both inhibited uncompetitively by neomycin 
with Ki values that did not differ si~ificantly from 
the Ki determined above against various ornithine 
concentrations: (I) Ki = 1.5 ? 0.3; (II) Ki = 1.8 + 
0.4 mM. Putrescine inhibited ODC competi- 
tively with Ki = 1.7 -+ 1.4 mM. 
DISCUSSION 
The characteristics of guinea pig renal ODC from 
the soluble, postmitochondrial supernatant fraction 
agree well with those from other species: the K, 
for ornithine (61 ,&f) is within the range of other 
reported K,,, values (60-200 PM) and the enzyme is 
inhibited by 0.1 to OSmM DFMO [7, lo]. Com- 
petitive inhibition by putrescine is also in agreement 
with the effects of putrescine on ODC in other tissues 
[7]. The presence of two K,,, values for PLP suggests 
that the renal enzyme exists in two forms which 
are distinguished by their affinity to PLP but not 
ornithine. Two forms of ODC with respect to their 
K, for PLP have been reported for Physarum poly- 
cephalum [ll], Swiss 3T3 mouse fibroblasts [X2] and 
Dictyostelium discoideum [13]. 
The salient point of this study is the finding that 
aminoglycoside ~tibioti~ inhibited renal ODC. 
Nephrotoxicity and ototoxicity of these drugs have 
been recognized for over 40 years; however, only 
recently has a plausible hypothesis been proposed to 
explain the complex sequence of events involved in 
the development of toxicity [6]. Inhibition of ODC 
may play an important role in this process by inter- 
fering with critical control mechanisms in the physi- 
ology of the target cells since the polyamines serve as 
important effecters in cellular growth, maintenance, 
and repair processes [7]. Points in favor of a role of 
this action in the expression of toxicity are the facts 
that neomycin has also been shown to inhibit coch- 
lear ODC [14] and that the inhibitor constants for 
the aminoglycosides are in the low millimolar range 
for the renal enzyme. Such concentrations can be 
achieved in uivo in the kidney, particularly the 
cortex, following systemic administration of the 
drugs [15-181. 
On the other hand, ODC is a ubiquitous enzyme 
and thus is a potential target of these drugs in other 
tissues as well. It has been suggested previously that 
the selective toxicity of the aminoglycosides is a 
result of several discrete biochemical interactions 
(61. These include an active uptake process in com- 
petition with the polyamines, and disturbance of cell 
function through inhibition of polyphosphoinositide 
metabolism. In addition, specificity may also par- 
tially be attributed to the fact that renal amino- 
glycoside concentrations are several orders of 
magnitude higher than those found in other tissues 
[19]. This means that ODC is only inhibited by 
aminoglycosides if high enough intracellul~ drug 
concentrations are reached. The observation that the 
respective inhibitor constants of the aminoglycosides 
for ODC do not correlate directly with the rank order 
of nephrotoxicity (or for that matter ototoxicity) of 
these drugs [18] is in good agreement with the notion 
that inhibition of ODC may represent a major com- 
ponent of a complex injury cascade [6] rather than 
a single determining step. Inhibition of ODC, 
however, may constitute a crucial mechanism for the 
lethal effects of these drugs on susceptible cells. 
Induction of ODC has been shown to be an essen- 
tial component in compensatory cellular responses to 
injury. Enzyme activity and intracellular polyamine 
levels increase following cellular damage by a variety 
of noxious stimuli including toxic drugs [7, 8,201, 
apparently in order to adapt protein synthesis to 
repair processes. Inhibition of ODC by the amino- 
glycosides would then provide a potential mechanism 
by which cetlular recovery is blocked. Such a block 
may well represent a final biochemical insult Leading 
to death of susceptible cells. 
The question then arises as to the mechanism by 
which aminoglycosides inhibit ODC. Although our 
experiments did not directly address this problem, 
the uncompetitive inhibition suggests a potential site 
of action. Uncompetitive inhibition is an attack at 
the enzyme-substrate complex, in this case ODC- 
PLP-ornithine. PLP has been shown to react in vitro 
with the polyamine spermine and the aminoglycoside 
gentamicin [21,22] which appears to form a Schiff 
base and ring structure [23] with this coenzyme. The 
lethal effects of these drugs in the rat in viva can 
also be antagonized by PLP [23]. Since ODC has an 
absolute requirement for PLP [24], such an amino- 
glycoside action would be an example of modulation 
of catalytic activity through coenzyme inhibition [ 111. 
Our results thus suggest ODC as a target of amino- 
glycosides in susceptible cells. Inhibition of cellular 
repair mechanisms mediated by ODC may be an 
essential component in the complex mechanisms 
of ‘aminoglycoside-induced nephrotoxicity and 
ototoxicity. 
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